Global Cognitive Decline Market
Global Cognitive Decline Market

Cognitive Decline Comprehensive Study by Treatment (Symptomatic Therapies, Preventive Therapies), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Mail Order Pharmacies, Online Stores), Medication (Antiepileptic Drugs, Antipsychotic Drugs), Symptoms (Confusion, Poor Motor Coordination, Loss Of Short-Term Or Long-Term Memory, Identity Confusion, Impaired Judgment) Players and Region - Global Market Outlook to 2026

Cognitive Decline Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Dec 2021 Edition 200 Pages 218 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Cognitive Decline Market Scope
Cognitive decline is a normal aspect of the ageing process. It occurs at various times and affects various aspects of people's lives, but it also has the same overall effect. Simply put, cognitive decline meaning that your brain isn't working as well as it once did. This is not the same as cognitive impairment, which can be caused by damage, disease, or a higher rate of cognitive decline due to a variety of factors. Cognitive decline is a result of the ageing of neurons and the slowing of the brain's processing speed. The difference between the two is that as people age, they all experience cognitive decline.

The Cognitive Decline market study is segmented and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Cognitive Decline market throughout the predicted period.

Janssen Pharmaceuticals Inc. (Belgium), Fresenius Kabi (Germany), Baxter Laboratories (United States), Biogen (United States), Eisai (Japan), Pfizer (United States), Strides Pharma (India) and Hikma Pharmaceuticals USA Inc. (United States) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AMA Research has segmented the market of Global Cognitive Decline market by Type, Application and Region.

On the basis of geography, the market of Cognitive Decline has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

On 5 November 2020, Nestle Health Science is launching a ketogenic drink to help fight mild cognitive impairment (MCI), a condition that affects between 15-20% of people aged 60 years and older. and On 21 July 2021, Ajinomoto has launched a supplement, backed by a clinical trial, to reduce the risk of cognitive decline in healthy middle-aged persons and elderly experiencing some form of memory impairment


Market Trend
  • Increased Investment R&D Activities In The Cognitive Decline

Market Drivers
  • Increasing Number Of Brain Disease Patients
  • Increasing Clinical Trial To Reduce The Risk Of Cognitive Decline

Opportunities
  • Increasing Incidence Of Cognitive Decline Due To Increased Geriatric Population

Restraints
  • Rising Case Of Medication Side Effect Of Cognitive Decline

Challenges
  • Lack Of Awareness About The Cognitive Decline Treatment Option


Key Target Audience
Cognitive Decline, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Frequently Asked Questions (FAQ):

1. Is it possible to have certain customization in the study?
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.

2. How big is the Cognitive Decline Market?
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.

Report Objectives / Segmentation Covered
By Treatment
  • Symptomatic Therapies
  • Preventive Therapies

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Mail Order Pharmacies
  • Online Stores

By Medication
  • Antiepileptic Drugs
  • Antipsychotic Drugs

By Symptoms
  • Confusion
  • Poor Motor Coordination
  • Loss Of Short-Term Or Long-Term Memory
  • Identity Confusion
  • Impaired Judgment

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number Of Brain Disease Patients
      • 3.2.2. Increasing Clinical Trial To Reduce The Risk Of Cognitive Decline
    • 3.3. Market Challenges
      • 3.3.1. Lack Of Awareness About The Cognitive Decline Treatment Option
    • 3.4. Market Trends
      • 3.4.1. Increased Investment R&D Activities In The Cognitive Decline
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Cognitive Decline, by Treatment, Distribution Channel, Medication , Symptoms and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Cognitive Decline (Value)
      • 5.2.1. Global Cognitive Decline by: Treatment (Value)
        • 5.2.1.1. Symptomatic Therapies
        • 5.2.1.2. Preventive Therapies
      • 5.2.2. Global Cognitive Decline by: Distribution Channel (Value)
        • 5.2.2.1. Hospital Pharmacies
        • 5.2.2.2. Retail Pharmacies
        • 5.2.2.3. Drug Stores
        • 5.2.2.4. Mail Order Pharmacies
        • 5.2.2.5. Online Stores
      • 5.2.3. Global Cognitive Decline by: Symptoms (Value)
        • 5.2.3.1. Confusion
        • 5.2.3.2. Poor Motor Coordination
        • 5.2.3.3. Loss Of Short-Term Or Long-Term Memory
        • 5.2.3.4. Identity Confusion
        • 5.2.3.5. Impaired Judgment
      • 5.2.4. Global Cognitive Decline Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Australia
          • 5.2.4.2.6. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Cognitive Decline (Price)
  • 6. Cognitive Decline: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Janssen Pharmaceuticals Inc. (Belgium)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Fresenius Kabi (Germany)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Baxter Laboratories (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Biogen (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Eisai (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Strides Pharma (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Hikma Pharmaceuticals USA Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Cognitive Decline Sale, by Treatment, Distribution Channel, Medication , Symptoms and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Cognitive Decline (Value)
      • 7.2.1. Global Cognitive Decline by: Treatment (Value)
        • 7.2.1.1. Symptomatic Therapies
        • 7.2.1.2. Preventive Therapies
      • 7.2.2. Global Cognitive Decline by: Distribution Channel (Value)
        • 7.2.2.1. Hospital Pharmacies
        • 7.2.2.2. Retail Pharmacies
        • 7.2.2.3. Drug Stores
        • 7.2.2.4. Mail Order Pharmacies
        • 7.2.2.5. Online Stores
      • 7.2.3. Global Cognitive Decline by: Symptoms (Value)
        • 7.2.3.1. Confusion
        • 7.2.3.2. Poor Motor Coordination
        • 7.2.3.3. Loss Of Short-Term Or Long-Term Memory
        • 7.2.3.4. Identity Confusion
        • 7.2.3.5. Impaired Judgment
      • 7.2.4. Global Cognitive Decline Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Australia
          • 7.2.4.2.6. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Cognitive Decline (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Cognitive Decline: by Treatment(USD Million)
  • Table 2. Cognitive Decline Symptomatic Therapies , by Region USD Million (2015-2020)
  • Table 3. Cognitive Decline Preventive Therapies , by Region USD Million (2015-2020)
  • Table 4. Cognitive Decline: by Distribution Channel(USD Million)
  • Table 5. Cognitive Decline Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 6. Cognitive Decline Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 7. Cognitive Decline Drug Stores , by Region USD Million (2015-2020)
  • Table 8. Cognitive Decline Mail Order Pharmacies , by Region USD Million (2015-2020)
  • Table 9. Cognitive Decline Online Stores , by Region USD Million (2015-2020)
  • Table 10. Cognitive Decline: by Symptoms(USD Million)
  • Table 11. Cognitive Decline Confusion , by Region USD Million (2015-2020)
  • Table 12. Cognitive Decline Poor Motor Coordination , by Region USD Million (2015-2020)
  • Table 13. Cognitive Decline Loss Of Short-Term Or Long-Term Memory , by Region USD Million (2015-2020)
  • Table 14. Cognitive Decline Identity Confusion , by Region USD Million (2015-2020)
  • Table 15. Cognitive Decline Impaired Judgment , by Region USD Million (2015-2020)
  • Table 16. South America Cognitive Decline, by Country USD Million (2015-2020)
  • Table 17. South America Cognitive Decline, by Treatment USD Million (2015-2020)
  • Table 18. South America Cognitive Decline, by Distribution Channel USD Million (2015-2020)
  • Table 19. South America Cognitive Decline, by Medication USD Million (2015-2020)
  • Table 20. South America Cognitive Decline, by Symptoms USD Million (2015-2020)
  • Table 21. Brazil Cognitive Decline, by Treatment USD Million (2015-2020)
  • Table 22. Brazil Cognitive Decline, by Distribution Channel USD Million (2015-2020)
  • Table 23. Brazil Cognitive Decline, by Medication USD Million (2015-2020)
  • Table 24. Brazil Cognitive Decline, by Symptoms USD Million (2015-2020)
  • Table 25. Argentina Cognitive Decline, by Treatment USD Million (2015-2020)
  • Table 26. Argentina Cognitive Decline, by Distribution Channel USD Million (2015-2020)
  • Table 27. Argentina Cognitive Decline, by Medication USD Million (2015-2020)
  • Table 28. Argentina Cognitive Decline, by Symptoms USD Million (2015-2020)
  • Table 29. Rest of South America Cognitive Decline, by Treatment USD Million (2015-2020)
  • Table 30. Rest of South America Cognitive Decline, by Distribution Channel USD Million (2015-2020)
  • Table 31. Rest of South America Cognitive Decline, by Medication USD Million (2015-2020)
  • Table 32. Rest of South America Cognitive Decline, by Symptoms USD Million (2015-2020)
  • Table 33. Asia Pacific Cognitive Decline, by Country USD Million (2015-2020)
  • Table 34. Asia Pacific Cognitive Decline, by Treatment USD Million (2015-2020)
  • Table 35. Asia Pacific Cognitive Decline, by Distribution Channel USD Million (2015-2020)
  • Table 36. Asia Pacific Cognitive Decline, by Medication USD Million (2015-2020)
  • Table 37. Asia Pacific Cognitive Decline, by Symptoms USD Million (2015-2020)
  • Table 38. China Cognitive Decline, by Treatment USD Million (2015-2020)
  • Table 39. China Cognitive Decline, by Distribution Channel USD Million (2015-2020)
  • Table 40. China Cognitive Decline, by Medication USD Million (2015-2020)
  • Table 41. China Cognitive Decline, by Symptoms USD Million (2015-2020)
  • Table 42. Japan Cognitive Decline, by Treatment USD Million (2015-2020)
  • Table 43. Japan Cognitive Decline, by Distribution Channel USD Million (2015-2020)
  • Table 44. Japan Cognitive Decline, by Medication USD Million (2015-2020)
  • Table 45. Japan Cognitive Decline, by Symptoms USD Million (2015-2020)
  • Table 46. India Cognitive Decline, by Treatment USD Million (2015-2020)
  • Table 47. India Cognitive Decline, by Distribution Channel USD Million (2015-2020)
  • Table 48. India Cognitive Decline, by Medication USD Million (2015-2020)
  • Table 49. India Cognitive Decline, by Symptoms USD Million (2015-2020)
  • Table 50. South Korea Cognitive Decline, by Treatment USD Million (2015-2020)
  • Table 51. South Korea Cognitive Decline, by Distribution Channel USD Million (2015-2020)
  • Table 52. South Korea Cognitive Decline, by Medication USD Million (2015-2020)
  • Table 53. South Korea Cognitive Decline, by Symptoms USD Million (2015-2020)
  • Table 54. Australia Cognitive Decline, by Treatment USD Million (2015-2020)
  • Table 55. Australia Cognitive Decline, by Distribution Channel USD Million (2015-2020)
  • Table 56. Australia Cognitive Decline, by Medication USD Million (2015-2020)
  • Table 57. Australia Cognitive Decline, by Symptoms USD Million (2015-2020)
  • Table 58. Rest of Asia-Pacific Cognitive Decline, by Treatment USD Million (2015-2020)
  • Table 59. Rest of Asia-Pacific Cognitive Decline, by Distribution Channel USD Million (2015-2020)
  • Table 60. Rest of Asia-Pacific Cognitive Decline, by Medication USD Million (2015-2020)
  • Table 61. Rest of Asia-Pacific Cognitive Decline, by Symptoms USD Million (2015-2020)
  • Table 62. Europe Cognitive Decline, by Country USD Million (2015-2020)
  • Table 63. Europe Cognitive Decline, by Treatment USD Million (2015-2020)
  • Table 64. Europe Cognitive Decline, by Distribution Channel USD Million (2015-2020)
  • Table 65. Europe Cognitive Decline, by Medication USD Million (2015-2020)
  • Table 66. Europe Cognitive Decline, by Symptoms USD Million (2015-2020)
  • Table 67. Germany Cognitive Decline, by Treatment USD Million (2015-2020)
  • Table 68. Germany Cognitive Decline, by Distribution Channel USD Million (2015-2020)
  • Table 69. Germany Cognitive Decline, by Medication USD Million (2015-2020)
  • Table 70. Germany Cognitive Decline, by Symptoms USD Million (2015-2020)
  • Table 71. France Cognitive Decline, by Treatment USD Million (2015-2020)
  • Table 72. France Cognitive Decline, by Distribution Channel USD Million (2015-2020)
  • Table 73. France Cognitive Decline, by Medication USD Million (2015-2020)
  • Table 74. France Cognitive Decline, by Symptoms USD Million (2015-2020)
  • Table 75. Italy Cognitive Decline, by Treatment USD Million (2015-2020)
  • Table 76. Italy Cognitive Decline, by Distribution Channel USD Million (2015-2020)
  • Table 77. Italy Cognitive Decline, by Medication USD Million (2015-2020)
  • Table 78. Italy Cognitive Decline, by Symptoms USD Million (2015-2020)
  • Table 79. United Kingdom Cognitive Decline, by Treatment USD Million (2015-2020)
  • Table 80. United Kingdom Cognitive Decline, by Distribution Channel USD Million (2015-2020)
  • Table 81. United Kingdom Cognitive Decline, by Medication USD Million (2015-2020)
  • Table 82. United Kingdom Cognitive Decline, by Symptoms USD Million (2015-2020)
  • Table 83. Netherlands Cognitive Decline, by Treatment USD Million (2015-2020)
  • Table 84. Netherlands Cognitive Decline, by Distribution Channel USD Million (2015-2020)
  • Table 85. Netherlands Cognitive Decline, by Medication USD Million (2015-2020)
  • Table 86. Netherlands Cognitive Decline, by Symptoms USD Million (2015-2020)
  • Table 87. Rest of Europe Cognitive Decline, by Treatment USD Million (2015-2020)
  • Table 88. Rest of Europe Cognitive Decline, by Distribution Channel USD Million (2015-2020)
  • Table 89. Rest of Europe Cognitive Decline, by Medication USD Million (2015-2020)
  • Table 90. Rest of Europe Cognitive Decline, by Symptoms USD Million (2015-2020)
  • Table 91. MEA Cognitive Decline, by Country USD Million (2015-2020)
  • Table 92. MEA Cognitive Decline, by Treatment USD Million (2015-2020)
  • Table 93. MEA Cognitive Decline, by Distribution Channel USD Million (2015-2020)
  • Table 94. MEA Cognitive Decline, by Medication USD Million (2015-2020)
  • Table 95. MEA Cognitive Decline, by Symptoms USD Million (2015-2020)
  • Table 96. Middle East Cognitive Decline, by Treatment USD Million (2015-2020)
  • Table 97. Middle East Cognitive Decline, by Distribution Channel USD Million (2015-2020)
  • Table 98. Middle East Cognitive Decline, by Medication USD Million (2015-2020)
  • Table 99. Middle East Cognitive Decline, by Symptoms USD Million (2015-2020)
  • Table 100. Africa Cognitive Decline, by Treatment USD Million (2015-2020)
  • Table 101. Africa Cognitive Decline, by Distribution Channel USD Million (2015-2020)
  • Table 102. Africa Cognitive Decline, by Medication USD Million (2015-2020)
  • Table 103. Africa Cognitive Decline, by Symptoms USD Million (2015-2020)
  • Table 104. North America Cognitive Decline, by Country USD Million (2015-2020)
  • Table 105. North America Cognitive Decline, by Treatment USD Million (2015-2020)
  • Table 106. North America Cognitive Decline, by Distribution Channel USD Million (2015-2020)
  • Table 107. North America Cognitive Decline, by Medication USD Million (2015-2020)
  • Table 108. North America Cognitive Decline, by Symptoms USD Million (2015-2020)
  • Table 109. United States Cognitive Decline, by Treatment USD Million (2015-2020)
  • Table 110. United States Cognitive Decline, by Distribution Channel USD Million (2015-2020)
  • Table 111. United States Cognitive Decline, by Medication USD Million (2015-2020)
  • Table 112. United States Cognitive Decline, by Symptoms USD Million (2015-2020)
  • Table 113. Canada Cognitive Decline, by Treatment USD Million (2015-2020)
  • Table 114. Canada Cognitive Decline, by Distribution Channel USD Million (2015-2020)
  • Table 115. Canada Cognitive Decline, by Medication USD Million (2015-2020)
  • Table 116. Canada Cognitive Decline, by Symptoms USD Million (2015-2020)
  • Table 117. Mexico Cognitive Decline, by Treatment USD Million (2015-2020)
  • Table 118. Mexico Cognitive Decline, by Distribution Channel USD Million (2015-2020)
  • Table 119. Mexico Cognitive Decline, by Medication USD Million (2015-2020)
  • Table 120. Mexico Cognitive Decline, by Symptoms USD Million (2015-2020)
  • Table 121. Company Basic Information, Sales Area and Its Competitors
  • Table 122. Company Basic Information, Sales Area and Its Competitors
  • Table 123. Company Basic Information, Sales Area and Its Competitors
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Cognitive Decline: by Treatment(USD Million)
  • Table 130. Cognitive Decline Symptomatic Therapies , by Region USD Million (2021-2026)
  • Table 131. Cognitive Decline Preventive Therapies , by Region USD Million (2021-2026)
  • Table 132. Cognitive Decline: by Distribution Channel(USD Million)
  • Table 133. Cognitive Decline Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 134. Cognitive Decline Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 135. Cognitive Decline Drug Stores , by Region USD Million (2021-2026)
  • Table 136. Cognitive Decline Mail Order Pharmacies , by Region USD Million (2021-2026)
  • Table 137. Cognitive Decline Online Stores , by Region USD Million (2021-2026)
  • Table 138. Cognitive Decline: by Symptoms(USD Million)
  • Table 139. Cognitive Decline Confusion , by Region USD Million (2021-2026)
  • Table 140. Cognitive Decline Poor Motor Coordination , by Region USD Million (2021-2026)
  • Table 141. Cognitive Decline Loss Of Short-Term Or Long-Term Memory , by Region USD Million (2021-2026)
  • Table 142. Cognitive Decline Identity Confusion , by Region USD Million (2021-2026)
  • Table 143. Cognitive Decline Impaired Judgment , by Region USD Million (2021-2026)
  • Table 144. South America Cognitive Decline, by Country USD Million (2021-2026)
  • Table 145. South America Cognitive Decline, by Treatment USD Million (2021-2026)
  • Table 146. South America Cognitive Decline, by Distribution Channel USD Million (2021-2026)
  • Table 147. South America Cognitive Decline, by Medication USD Million (2021-2026)
  • Table 148. South America Cognitive Decline, by Symptoms USD Million (2021-2026)
  • Table 149. Brazil Cognitive Decline, by Treatment USD Million (2021-2026)
  • Table 150. Brazil Cognitive Decline, by Distribution Channel USD Million (2021-2026)
  • Table 151. Brazil Cognitive Decline, by Medication USD Million (2021-2026)
  • Table 152. Brazil Cognitive Decline, by Symptoms USD Million (2021-2026)
  • Table 153. Argentina Cognitive Decline, by Treatment USD Million (2021-2026)
  • Table 154. Argentina Cognitive Decline, by Distribution Channel USD Million (2021-2026)
  • Table 155. Argentina Cognitive Decline, by Medication USD Million (2021-2026)
  • Table 156. Argentina Cognitive Decline, by Symptoms USD Million (2021-2026)
  • Table 157. Rest of South America Cognitive Decline, by Treatment USD Million (2021-2026)
  • Table 158. Rest of South America Cognitive Decline, by Distribution Channel USD Million (2021-2026)
  • Table 159. Rest of South America Cognitive Decline, by Medication USD Million (2021-2026)
  • Table 160. Rest of South America Cognitive Decline, by Symptoms USD Million (2021-2026)
  • Table 161. Asia Pacific Cognitive Decline, by Country USD Million (2021-2026)
  • Table 162. Asia Pacific Cognitive Decline, by Treatment USD Million (2021-2026)
  • Table 163. Asia Pacific Cognitive Decline, by Distribution Channel USD Million (2021-2026)
  • Table 164. Asia Pacific Cognitive Decline, by Medication USD Million (2021-2026)
  • Table 165. Asia Pacific Cognitive Decline, by Symptoms USD Million (2021-2026)
  • Table 166. China Cognitive Decline, by Treatment USD Million (2021-2026)
  • Table 167. China Cognitive Decline, by Distribution Channel USD Million (2021-2026)
  • Table 168. China Cognitive Decline, by Medication USD Million (2021-2026)
  • Table 169. China Cognitive Decline, by Symptoms USD Million (2021-2026)
  • Table 170. Japan Cognitive Decline, by Treatment USD Million (2021-2026)
  • Table 171. Japan Cognitive Decline, by Distribution Channel USD Million (2021-2026)
  • Table 172. Japan Cognitive Decline, by Medication USD Million (2021-2026)
  • Table 173. Japan Cognitive Decline, by Symptoms USD Million (2021-2026)
  • Table 174. India Cognitive Decline, by Treatment USD Million (2021-2026)
  • Table 175. India Cognitive Decline, by Distribution Channel USD Million (2021-2026)
  • Table 176. India Cognitive Decline, by Medication USD Million (2021-2026)
  • Table 177. India Cognitive Decline, by Symptoms USD Million (2021-2026)
  • Table 178. South Korea Cognitive Decline, by Treatment USD Million (2021-2026)
  • Table 179. South Korea Cognitive Decline, by Distribution Channel USD Million (2021-2026)
  • Table 180. South Korea Cognitive Decline, by Medication USD Million (2021-2026)
  • Table 181. South Korea Cognitive Decline, by Symptoms USD Million (2021-2026)
  • Table 182. Australia Cognitive Decline, by Treatment USD Million (2021-2026)
  • Table 183. Australia Cognitive Decline, by Distribution Channel USD Million (2021-2026)
  • Table 184. Australia Cognitive Decline, by Medication USD Million (2021-2026)
  • Table 185. Australia Cognitive Decline, by Symptoms USD Million (2021-2026)
  • Table 186. Rest of Asia-Pacific Cognitive Decline, by Treatment USD Million (2021-2026)
  • Table 187. Rest of Asia-Pacific Cognitive Decline, by Distribution Channel USD Million (2021-2026)
  • Table 188. Rest of Asia-Pacific Cognitive Decline, by Medication USD Million (2021-2026)
  • Table 189. Rest of Asia-Pacific Cognitive Decline, by Symptoms USD Million (2021-2026)
  • Table 190. Europe Cognitive Decline, by Country USD Million (2021-2026)
  • Table 191. Europe Cognitive Decline, by Treatment USD Million (2021-2026)
  • Table 192. Europe Cognitive Decline, by Distribution Channel USD Million (2021-2026)
  • Table 193. Europe Cognitive Decline, by Medication USD Million (2021-2026)
  • Table 194. Europe Cognitive Decline, by Symptoms USD Million (2021-2026)
  • Table 195. Germany Cognitive Decline, by Treatment USD Million (2021-2026)
  • Table 196. Germany Cognitive Decline, by Distribution Channel USD Million (2021-2026)
  • Table 197. Germany Cognitive Decline, by Medication USD Million (2021-2026)
  • Table 198. Germany Cognitive Decline, by Symptoms USD Million (2021-2026)
  • Table 199. France Cognitive Decline, by Treatment USD Million (2021-2026)
  • Table 200. France Cognitive Decline, by Distribution Channel USD Million (2021-2026)
  • Table 201. France Cognitive Decline, by Medication USD Million (2021-2026)
  • Table 202. France Cognitive Decline, by Symptoms USD Million (2021-2026)
  • Table 203. Italy Cognitive Decline, by Treatment USD Million (2021-2026)
  • Table 204. Italy Cognitive Decline, by Distribution Channel USD Million (2021-2026)
  • Table 205. Italy Cognitive Decline, by Medication USD Million (2021-2026)
  • Table 206. Italy Cognitive Decline, by Symptoms USD Million (2021-2026)
  • Table 207. United Kingdom Cognitive Decline, by Treatment USD Million (2021-2026)
  • Table 208. United Kingdom Cognitive Decline, by Distribution Channel USD Million (2021-2026)
  • Table 209. United Kingdom Cognitive Decline, by Medication USD Million (2021-2026)
  • Table 210. United Kingdom Cognitive Decline, by Symptoms USD Million (2021-2026)
  • Table 211. Netherlands Cognitive Decline, by Treatment USD Million (2021-2026)
  • Table 212. Netherlands Cognitive Decline, by Distribution Channel USD Million (2021-2026)
  • Table 213. Netherlands Cognitive Decline, by Medication USD Million (2021-2026)
  • Table 214. Netherlands Cognitive Decline, by Symptoms USD Million (2021-2026)
  • Table 215. Rest of Europe Cognitive Decline, by Treatment USD Million (2021-2026)
  • Table 216. Rest of Europe Cognitive Decline, by Distribution Channel USD Million (2021-2026)
  • Table 217. Rest of Europe Cognitive Decline, by Medication USD Million (2021-2026)
  • Table 218. Rest of Europe Cognitive Decline, by Symptoms USD Million (2021-2026)
  • Table 219. MEA Cognitive Decline, by Country USD Million (2021-2026)
  • Table 220. MEA Cognitive Decline, by Treatment USD Million (2021-2026)
  • Table 221. MEA Cognitive Decline, by Distribution Channel USD Million (2021-2026)
  • Table 222. MEA Cognitive Decline, by Medication USD Million (2021-2026)
  • Table 223. MEA Cognitive Decline, by Symptoms USD Million (2021-2026)
  • Table 224. Middle East Cognitive Decline, by Treatment USD Million (2021-2026)
  • Table 225. Middle East Cognitive Decline, by Distribution Channel USD Million (2021-2026)
  • Table 226. Middle East Cognitive Decline, by Medication USD Million (2021-2026)
  • Table 227. Middle East Cognitive Decline, by Symptoms USD Million (2021-2026)
  • Table 228. Africa Cognitive Decline, by Treatment USD Million (2021-2026)
  • Table 229. Africa Cognitive Decline, by Distribution Channel USD Million (2021-2026)
  • Table 230. Africa Cognitive Decline, by Medication USD Million (2021-2026)
  • Table 231. Africa Cognitive Decline, by Symptoms USD Million (2021-2026)
  • Table 232. North America Cognitive Decline, by Country USD Million (2021-2026)
  • Table 233. North America Cognitive Decline, by Treatment USD Million (2021-2026)
  • Table 234. North America Cognitive Decline, by Distribution Channel USD Million (2021-2026)
  • Table 235. North America Cognitive Decline, by Medication USD Million (2021-2026)
  • Table 236. North America Cognitive Decline, by Symptoms USD Million (2021-2026)
  • Table 237. United States Cognitive Decline, by Treatment USD Million (2021-2026)
  • Table 238. United States Cognitive Decline, by Distribution Channel USD Million (2021-2026)
  • Table 239. United States Cognitive Decline, by Medication USD Million (2021-2026)
  • Table 240. United States Cognitive Decline, by Symptoms USD Million (2021-2026)
  • Table 241. Canada Cognitive Decline, by Treatment USD Million (2021-2026)
  • Table 242. Canada Cognitive Decline, by Distribution Channel USD Million (2021-2026)
  • Table 243. Canada Cognitive Decline, by Medication USD Million (2021-2026)
  • Table 244. Canada Cognitive Decline, by Symptoms USD Million (2021-2026)
  • Table 245. Mexico Cognitive Decline, by Treatment USD Million (2021-2026)
  • Table 246. Mexico Cognitive Decline, by Distribution Channel USD Million (2021-2026)
  • Table 247. Mexico Cognitive Decline, by Medication USD Million (2021-2026)
  • Table 248. Mexico Cognitive Decline, by Symptoms USD Million (2021-2026)
  • Table 249. Research Programs/Design for This Report
  • Table 250. Key Data Information from Secondary Sources
  • Table 251. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Cognitive Decline: by Treatment USD Million (2015-2020)
  • Figure 5. Global Cognitive Decline: by Distribution Channel USD Million (2015-2020)
  • Figure 6. Global Cognitive Decline: by Symptoms USD Million (2015-2020)
  • Figure 7. South America Cognitive Decline Share (%), by Country
  • Figure 8. Asia Pacific Cognitive Decline Share (%), by Country
  • Figure 9. Europe Cognitive Decline Share (%), by Country
  • Figure 10. MEA Cognitive Decline Share (%), by Country
  • Figure 11. North America Cognitive Decline Share (%), by Country
  • Figure 12. Global Cognitive Decline share by Players 2020 (%)
  • Figure 13. Global Cognitive Decline share by Players (Top 3) 2020(%)
  • Figure 14. Global Cognitive Decline share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Janssen Pharmaceuticals Inc. (Belgium) Revenue, Net Income and Gross profit
  • Figure 17. Janssen Pharmaceuticals Inc. (Belgium) Revenue: by Geography 2020
  • Figure 18. Fresenius Kabi (Germany) Revenue, Net Income and Gross profit
  • Figure 19. Fresenius Kabi (Germany) Revenue: by Geography 2020
  • Figure 20. Baxter Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 21. Baxter Laboratories (United States) Revenue: by Geography 2020
  • Figure 22. Biogen (United States) Revenue, Net Income and Gross profit
  • Figure 23. Biogen (United States) Revenue: by Geography 2020
  • Figure 24. Eisai (Japan) Revenue, Net Income and Gross profit
  • Figure 25. Eisai (Japan) Revenue: by Geography 2020
  • Figure 26. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 27. Pfizer (United States) Revenue: by Geography 2020
  • Figure 28. Strides Pharma (India) Revenue, Net Income and Gross profit
  • Figure 29. Strides Pharma (India) Revenue: by Geography 2020
  • Figure 30. Hikma Pharmaceuticals USA Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Hikma Pharmaceuticals USA Inc. (United States) Revenue: by Geography 2020
  • Figure 32. Global Cognitive Decline: by Treatment USD Million (2021-2026)
  • Figure 33. Global Cognitive Decline: by Distribution Channel USD Million (2021-2026)
  • Figure 34. Global Cognitive Decline: by Symptoms USD Million (2021-2026)
  • Figure 35. South America Cognitive Decline Share (%), by Country
  • Figure 36. Asia Pacific Cognitive Decline Share (%), by Country
  • Figure 37. Europe Cognitive Decline Share (%), by Country
  • Figure 38. MEA Cognitive Decline Share (%), by Country
  • Figure 39. North America Cognitive Decline Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Janssen Pharmaceuticals Inc. (Belgium)
  • Fresenius Kabi (Germany)
  • Baxter Laboratories (United States)
  • Biogen (United States)
  • Eisai (Japan)
  • Pfizer (United States)
  • Strides Pharma (India)
  • Hikma Pharmaceuticals USA Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation